Stock Detail
OPTIMER PHARMACEUTICALS INC
Biotechnology
OPTR @ Yahoo Finance | OPTR Option @ Yahoo Finance
Last Day's Data
| Current Price | High | Value Change | Percent Change | Dividend | Previous Close |
|---|---|---|---|---|---|
| $11.18 | $11.52 | $-0.26 | -2.27% | 0.00 | $11.44 |
| Opening Price | Low | Volume | Market Cap | Average Volume | P/E |
| $11.33 | $11.15 | 442,779 | 521.49M | 1.38M | -26.62 |
Pivot Table
| R2 | R1 | Pivot | S1 | S2 |
| 11.65 | 11.41 | 11.28 | 11.04 | 10.91 |
Stock Profile
Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products primarily to treat gastrointestinal infections and related diseases. Its product candidates include Difimicin (OPT-80), which is in Phase 3 registration trial for the treatment of Clostridium Difficile-associated diarrhea (CDAD), and for the prevention of CDAD; and prevention of nosocomial vancomycin-resistant enterococci bloodstream infections, and methicillin-resistant staphylococci prophylaxis. The company is also developing Prulifloxacin, which is under Phase 3 trial for the treatment of infectious diarrhea, including traveler's diarrhea; OPT-88, a therapy for osteoarthritis; OPT-822/OPT-821, a cancer immunotherapy for the treatment of metastatic breast cancer; and OPT-1068 and OPT-1273 antibiotics for the treatment of upper and lower respiratory tract infections. It has a collaboration agreement with Par Pharmaceutical, Inc. for the clinical development and commercialization of Difimicin; as well as a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds. Optimer Pharmaceuticals was founded in 1998 and is headquartered in San Diego, California.